Can a walking program with text reminders and social support boost health in adults with intellectual disabilities?

NCT ID NCT04573530

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a program called We Walk Plus, which uses a Fitbit activity tracker, personalized text messages, and a private social network to encourage walking in 46 adults aged 35-60 with mild or moderate intellectual disabilities. The goal is to see if the program is feasible and acceptable, and whether it can increase daily steps and improve cognition. Participants will wear the Fitbit, receive SMS reminders, and connect with others in a private online community.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
We Walk Plus intervention (personalized SMS, Fitbit activity monitor, private social network)
What this could lead to
If successful, this could point toward a simple, low-cost way to help older adults with intellectual disabilities become more active and potentially improve their thinking skills.
What could go wrong
This is a small feasibility study with only 46 participants, so results may not apply to everyone. The program relies on support from family or staff, which may limit its use in other settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTELLECTUAL DISABILITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Trinity Services Inc.

    New Lenox, Illinois, 60451, United States

  • University of Illinois at Chicago

    Chicago, Illinois, 60608, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.